French “sunshine act” sheds little light on drug industry’s payments to doctors, say criticsBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3762 (Published 11 June 2013) Cite this as: BMJ 2013;346:f3762
- Paul Benkimoun
The French government passed into law its long awaited version of a “sunshine act” on 22 May, putting a legal obligation on drug companies to reveal the financial gifts they bestow on healthcare practitioners.
Marisol Touraine, the minister of social affairs and health, said that the act was intended to provide a moral underpinning on “the relations between industry and the world of health.”
The new bill, which aims to prevent conflicts of interests, is a reference to the US Sunshine Act (Physician Financial Transparency Reports), which was included …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial